Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tianyin Pharmaceutical, a provider of modernized traditional Chinese medicine, has announced that it launched the production of Azithromycin dispersible tablets in August 2008 and is due to market the new product in October 2008.
Subscribe to our email newsletter
Tianyin has previously received the official approval from the Chinese State Food and Drug Administration (SFDA) to produce Azithromycin dispersible tablets in two dosage forms, 0.25gm and 0.1gm.
This is the third generic western medicine to be included in Tianyin’s product portfolio. The company will continue to diversify its traditional Chinese medicine products, with additional western medicines as it receives approvals for its drugs that are currently in the SFDA pipeline.
Jiang, chairman and CEO of Tianyin Pharmaceutical, said: “We are pleased to announce the formal launch and commercialization of Azithromycin dispersible tablets. We will immediately start marketing this widely used drug through our distribution partners and extensive sales network.
We currently maintain the capacity to produce approximately $1 million of Azithromycin annually and will expand this output during the coming year. We will continue to move additional drugs currently in our pipeline through the approval process toward commercialization which will enable us to achieve our goal in 2009.”